MICHELLE TRAN: Open Payments
NPI 1184393217 · SILVER SPRING, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$381 in 19 payments from 10 companies in 2025. Trend: 2023 $581 · 2024 $1,357 · 2025 $381
Food & beverage: $381
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $89 |
| Amgen Inc. | 3 | $67 |
| ABBVIE INC. | 3 | $67 |
| Novo Nordisk Inc | 3 | $49 |
| Seqirus USA Inc | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| PFIZER INC. | 1 | $19 |
| Abbott Laboratories | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Cranial Technologies, Inc | 1 | $14 |
Products named: OTEZLA, AIRSUPRA, UBRELVY, QULIPTA, Ozempic, FARXIGA, Fluad, BEXSERO.
Industry payments across MD — which companies pay providers there.
